Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice (NMJ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01682148
Recruitment Status : Terminated (The study was terminated early due to slow recruitment.)
First Posted : September 10, 2012
Results First Posted : February 18, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Ipsen

Brief Summary:
The aim of the study was to compare Dysport treatment results (as assessed by Modified Ashworth Scale (MAS) in the elbow joint 4 weeks post treatment) following two treatment techniques: the current clinical practice injection technique using high-concentration dilution (300 U/mL Dysport) versus the neuromuscular junction (NMJ)-targeted injection technique using low-concentration dilution (100 U/mL Dysport). The hypothesis was that one high-volume, low-concentration injection located centrally in the area/band of the NMJ zones would be as effective as the technique used in current medical practice.

Condition or disease Intervention/treatment Phase
Arm Spasticity Biological: Botulinum toxin type A Phase 3

Detailed Description:

This was a randomised, evaluator-blinded, comparative, parallel group, multicentre study, conducted in four countries (Denmark, Finland, Norway and Sweden). For each subject, the primary efficacy assessments using MAS were performed by the same blinded evaluator, and every effort was made at each site to ensure that the MAS evaluator was the same person throughout the study. Dysport doses were to follow clinical practice for subjects suffering from upper limb spasticity position pattern type 1, 3 or 4 post stroke or traumatic brain injury.

The hypothesis for this study was that one low-concentration botulinum neurotoxin type A (BoNT-A) injection per muscle, centrally located in the area/band of the NMJ zones, would spread to and block the surrounding NMJ zones and be as effective as the technique used today in clinical practice. The possibility to reduce the number of injection points would decrease the risk of injection discomfort, pain and injection site bleeding for the patient. A simplified injection technique with one injection per muscle and in a defined location would also benefit physicians.

At Baseline (Visit 1), subjects were randomised to one of two treatment groups:

  • Group 1: Current clinical practice technique and high-concentration dilution: Dysport 300 U/mL.
  • Group 2: NMJ targeted technique and low-concentration dilution: Dysport 100 U/mL.

Each subject visited the clinic on at least three occasions:

  • Baseline (Visit 1): Screening, randomisation and Dysport treatment.
  • Week 4 (Visit 2): Treatment follow-up, 4 weeks after Dysport treatment.
  • Week 12 (Visit 3): Treatment and study follow-up, 12 weeks after Dysport treatment.

For subjects not receiving any post study BoNT-A injection at Week 12 due to remaining treatment effect, an extra visit (Visit 4) for study follow-up was to take place at the next routine visit planned for a new BoNT-A injection, at the latest 24 weeks post study injection.

The duration of each subject's study period was at a minimum 12 weeks and maximum 24 weeks. The overall duration of the study was planned to be approximately 36 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice
Study Start Date : September 2012
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Arm Intervention/treatment
Experimental: NMJ Targeted
NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
Biological: Botulinum toxin type A
Other Name: AbobotulinumtoxinA (Dysport®)

Active Comparator: Current Clinical Practice

Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).

A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.

Biological: Botulinum toxin type A
Other Name: AbobotulinumtoxinA (Dysport®)




Primary Outcome Measures :
  1. Change From Baseline for Elbow Flexors Muscle Tone as Measured by the Modified Ashworth Scale (MAS) at Week 4 [ Time Frame: Baseline to Week 4 ]
    A clinically relevant change was one level decrease on the MAS scale. Subjects meeting the defined decrease at Week 4 were considered as responders in the primary efficacy analysis.


Secondary Outcome Measures :
  1. Change From Baseline for Elbow Flexors Muscle Tone as Measured by the Modified Ashworth Scale (MAS) at Week 4 and Week 12 [ Time Frame: Baseline to Week 12 ]
    Increased muscle tone in elbow flexors was assessed using the MAS. Scale ranges from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension).

  2. Change From Baseline for Elbow Flexors Muscle Tone as Measured by the MAS at Week 12 [ Time Frame: Baseline to Week 12 ]
    A clinically relevant change was one level decrease on the MAS scale. Subjects meeting the defined decrease at Week 12 were considered as responders.

  3. Change From Baseline of Spasticity Related Pain Measured by Visual Analogue Scale (VAS), Assessed by the Subject [ Time Frame: Baseline, Week 4 and Week 12 ]
    Pain assessment using the VAS. The VAS was a 10 cm straight horizontal line scoring scale. Score range on VAS was from 0 to 10 where 0 indicated no pain and 10 indicated worst pain imaginable.

  4. Injection Site Pain Measured by VAS at Day 1. [ Time Frame: Baseline ]
    Pain assessment using the VAS. The VAS was a 100 mm straight horizontal line scoring scale. Score range on VAS was from 0 to 100 where 0 indicated no pain and 100 indicated worst pain imaginable.

  5. Achievement of the Primary Goal Measured by Goal Attainment Scale (GAS) [ Time Frame: Up to Week 12 ]
    At Baseline, an agreed primary goal related to elbow flexion in one of the following categories was determined: active function, impairment, involuntary movement, mobility, pain passive function or other. Each goal was usually rated -1, unless the subject was as bad as he/she could be in that particular goal area, in which case the Baseline score was -2. The evaluator rated the outcome score at Week 4 or Week 12, depending on the time point defined at the baseline visit (Visit 1), using the GAS five-point scale (-2, -1, 0, +1 and +2).

  6. Subject Global Evaluation of Treatment Effect [ Time Frame: Up to Week 24 ]
    Comparison of treatment effect between previous (prestudy) and study treatment cycles assessed by the subject at the end of study (Week 12 up to Week 24 (Visit 3 or Visit 4)). Categorised as follows: Much worse / Worse / Same / Better / Much better.

  7. Investigator Preference of Injection Technique [ Time Frame: Following last visit of the last subject at each site ]
    When all patients at the site had completed the study (last subject last visit) a global assessment of the injection technique was to be made by the Investigators. The following question was answered: "Based on your experience during this study, which injection technique do you prefer?"



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of written informed consent prior to any study related procedures.
  • Subjects male or female, aged 18 years or older.
  • Upper limb spasticity post stroke or traumatic brain injury.
  • Spasticity position pattern type 1, 3 or 4.
  • Elbow flexor muscles spasticity MAS 2 to 3.
  • At least 2 consecutive previous treatment cycles of BoNT-A for current diagnosis.
  • The latest treatment cycle demonstrating good treatment efficacy where the Dysport dose administered was considered to be adequate according to Investigator judgement.
  • Need of the same treatment modality in muscle (m.) brachialis, m. biceps brachii, m. brachioradialis, m. flexor carpi ulnaris, m. flexor carpi radialis as the previous treatment cycle.
  • Last BoNT-A treatment 12-24 weeks ago.

Exclusion Criteria:

  • Poor response to BoNT-A treatment, according to Investigator.
  • Need of Dysport doses >800 U in the upper limb.
  • Concomitant treatment with BoNT-A for other indications than spasticity.
  • Any elbow flexor contracture prohibiting MAS evaluation and/or elbow flexion improvement of at least 1 step on the MAS.
  • Cutaneous or joint inflammation in the affected upper limb.
  • Was likely to start other spasticity treatment during the study.
  • Was likely to start physiotherapy treatment during the study.
  • Other ongoing neurological disorder (e.g., myasthenia gravis).
  • History of dysphagia or aspiration.
  • Use of agents interfering with neuromuscular transmission (e.g., aminoglycosides).
  • Treated with an investigational medicinal product within 30 days before start of the study.
  • Known sensitivity to BoNT-A or any components of Dysport.
  • Was at risk of pregnancy or was lactating. Females of childbearing potential must have provided a negative pregnancy test (urinary human chorionic gonadotropin (U-hCG)) at Visit 1 and must have been using adequate contraception. Non-childbearing potential was defined as post-menopause for at least one year, surgical sterilisation or hysterectomy at least three months before the start of the study.
  • Had a history of, or known current, problems with alcohol or drug abuse.
  • Had a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
  • Had abnormal Baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might have jeopardised the subject's safety or decreased the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682148


Locations
Layout table for location information
Denmark
Aalborg Sygehus Nord
Aalborg, Denmark, 9000
Glostrup Hospital
Glostrup, Denmark, 2600
Regionshospitalet Hammel
Hammel, Denmark, 8450
Bispebjerg Hospital
København NV, Denmark, 2400
Roskilde Hospital
Roskilde, Denmark, 4000
Vejle Hospital
Vejle, Denmark, 7100
Regionshopsitalet Viborg
Viborg, Denmark, 8800
Finland
North Karelia Central Hospital
Joensuu, Finland, 80210
Central Hospital of Central Finland
Jyväskylä, Finland, 40503
Norway
Haukeland University Hospital
Bergen, Norway, 5021
Sykehuset Telemark HF
Skien, Norway, , 3700
Sweden
Mälarsjukhuset MSE
Eskilstuna, Sweden, 631-88
Sahlgrenska University Hospital
Göteborg, Sweden
Hallands Sjukhus, Neurology Clinic
Halmstad, Sweden, 30185
Sundsvall-Härnösand, Rehabilitation Medicine
Härnösand, Sweden, 87182
Nyköpings Lasarett,
Nyköping, Sweden, 61185
Neurology Clinic Stockholm
Stockholm, Sweden, 114 33
Danderyds Hospital,
Stockholm, Sweden, 18288
Neurorehab Sävar
Sävar, Sweden, 91831
Rehabilitation Center Gotland
Visby, Sweden, 62184
Ystad Lasarett
Ystad, Sweden, 27133
Örnsköldsviks Sjukhus, Neurology Clinic
Örnsköldsvik, Sweden, 891 89
Östersunds Rehabilitation Center
Östersund, Sweden, 83102
Sponsors and Collaborators
Ipsen
Investigators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT01682148     History of Changes
Other Study ID Numbers: A-99-52120-162
2011-005375-16 ( EudraCT Number )
First Posted: September 10, 2012    Key Record Dates
Results First Posted: February 18, 2019
Last Update Posted: August 6, 2019
Last Verified: July 2019

Keywords provided by Ipsen:
Dysport
arm spasticity
Modified Ashworth Scale
neuromuscular junction
Botulinum toxin
upper limb spasticity

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Botulinum Toxins
Botulinum Toxins, Type A
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents